Holen Sie sich die Stockscreener-App
29.62
2.95%
-0.90
Vorhandelsmarkt:
29.55
-0.07
-0.24%
Schlusskurs vom Vortag:
$30.52
Offen:
$30.14
24-Stunden-Volumen:
14.13M
Relative Volume:
0.75
Marktkapitalisierung:
$6.74B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
42.93
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-5.61%
1M Leistung:
-14.89%
6M Leistung:
-48.95%
1J Leistung:
-4.11%
1-Tages-Spanne:
$29.40
$30.99
1-Wochen-Bereich:
$27.96
$31.30
52-Wochen-Spanne:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.62 | 6.95B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
124.05 | 54.82B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.29 | 50.36B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.81 | 36.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.94 | 20.33B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Health: The Reset Nobody Expected (NYSE:HIMS) - Seeking Alpha
Y Intercept Hong Kong Ltd Grows Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
A Profitable Company Under Siege: The Curious Case of Hims & Hers - AD HOC NEWS
End Of Novo Nordisk GLP-1 Deal Could Be A Game Changer For Hims & Hers Health (HIMS) - Sahm
Peering Into Hims & Hers Health Inc's Recent Short Interest - Sahm
Lobbying Update: $330,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Healthcare Stocks To Keep An Eye OnJanuary 23rd - MarketBeat
Steadview Capital Management LLC Purchases 311,845 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
TipRanksXAI Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $31 - Futubull
183,304 Shares in Hims & Hers Health, Inc. $HIMS Acquired by Emerald Mutual Fund Advisers Trust - MarketBeat
How (HIMS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are the hidden costs of weight loss for Americans? - leader-call.com
Healthcare Stocks To ConsiderJanuary 22nd - MarketBeat
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling? - Yahoo Finance
Why Hims & Hers Stock Slipped Today - AOL.com
QRG Capital Management Inc. Decreases Stock Holdings in Hims & Hers Health, Inc. $HIMS - MarketBeat
Emerald Advisers LLC Acquires New Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock By Investing.com - Investing.com South Africa
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock - Investing.com
Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 9,067 Shares of Stock - MarketBeat
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.2%Here's Why - MarketBeat
Hims & Hers Health Inc. Stock (HIMS) Opinions on Recent Price Decline - Quiver Quantitative
Best Healthcare Stocks To ConsiderJanuary 5th - MarketBeat
Hims & Hers Health (NYSE:HIMS) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Top 3 Health Care Stocks That Could Blast Off This Month - Benzinga
Hims & Hers Health Stock Outlook: Modeling a 95% Upside Case - TIKR.com
Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets - MSN
Hims And Hers Wegovy Talks Could Reshape Growth And Subscriber Economics - simplywall.st
2 Top Stocks to Double Up On Right Now - Yahoo Finance
2 Top Stocks to Double Up On Right Now - The Motley Fool
Why Hims & Hers Health (HIMS) Stock Is Down Today - Finviz
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Hims & Hers Expands Platform-Led Access to Digital Healthcare - The Globe and Mail
Published on: 2026-01-18 05:20:30 - baoquankhu1.vn
Portfolio Recap: Does SKLZ stock benefit from AI growthJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Market Review: Is Hims Hers Health Inc a top pick in the sectorMarket Risk Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Hims GLP-1 Weight Loss Guide 2026: Injectable and Oral Treatment Options for Men (Semaglutide and Tirzepatide) - Newswire.com
Hims & Hers And HIMZ: Short‑Term Pain From Novo, Long‑Term Opportunity Still Bright (HIMS) - Seeking Alpha
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Hims & Hers Shares Face Heightened Volatility on Key Expiry Date - AD HOC NEWS
Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s - Sherwood News
Is Hims & Hers (HIMS) Using Zava to Balance GLP-1 Uncertainty with Broader Platform Ambitions? - Sahm
Promising Healthcare Stocks To Follow NowJanuary 14th - MarketBeat
BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) - Insider Monkey
Hims & Hers: Growth Catalysts Or Margin Trap (NYSE:HIMS) - Seeking Alpha
A Look At Hims & Hers Health (HIMS) Valuation As Amazon Targets The Weight Loss Segment - Sahm
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - MSN
OMCL vs. HIMS: Which Stock Is the Better Value Option? - Yahoo Finance
Belvedere Trading LLC Sells 35,095 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):